JWJ-01-306
JWJ-01-306 is a CRBN-recruiting ZBTB11 Molecular Glues degrader. JWJ-01-306 degrades ZBTB11 and reprograms cellular metabolism, thereby reducing the level of Oxidative Phosphorylation and the activity of the tricarboxylic acid cycle. JWJ-01-306 enhances the response of organoids to K-Ras inhibition. JWJ-01-306 inhibits the proliferation of pancreatic ductal adenocarcinoma cells and melanoma cells. JWJ-01-306 can be used in studies related to pancreatic ductal adenocarcinoma and melanoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 3069975-17-0
- 화학식: C28H26ClF3N4O4
- 분자량:574.98
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
In Vitro
JWJ-01-306 (10 μM; 5 h) potently degrades endogenous ZBTB11 in MIA PaCa-2 cells via a CRBN- and proteasome-dependent mechanism. As measured by HiBiT quantification, the Dmax reaches 60%; whereas detected by immunoblotting, the Dmax reaches 90%[1].
JWJ-01-306 (10 μM; 1-14 days) acts synergistically with Sotorasib (HY-114277) to potently inhibit the proliferation of sotorasib-resistant MIA PaCa-2 cells, degrade ZBTB11, specifically impair cellular oxidative phosphorylation, reduce the basal oxygen consumption rate, maximal oxygen consumption rate and mitoATP/glycoATP ratio, downregulate ZBTB11-mediated transcription of mitochondrial ribosomal and complex I genes, disrupt tricarboxylic acid (TCA) cycle flux in cells, and induce reductive glutamine metabolism[1].
JWJ-01-306 (10 μM; 1-6 days) potently inhibits the proliferation of parental and MRTX1133 (HY-134813)-resistant SUIT2 cells, enhances the antiproliferative effect of MRTX1133 in drug-resistant cells, impairs cellular oxidative phosphorylation, and reduces the basal oxygen consumption rate, maximum oxygen consumption rate, and mitoATP/glycoATP ratio[1].
JWJ-01-306 (1 μM; 7 days) enhances the antiproliferative activity of MRTX1133 in pancreatic cancer organoids and deepens the response to K-Ras inhibition[1].
JWJ-01-306 (5 h) potently degrades endogenous ZBTB11 in MOLT-4 cells with a DC50 of 0.28 μM, reaching a maximum degradation rate of 72% after 5 h of treatment. It also degrades endogenous IKZF1 in Jurkat cells with a DC50 of 0.03 μM, achieving a maximum degradation rate of 85% after 5 h of treatment[2].
JWJ-01-306 (10 μM; 24 h) reduces oxidative phosphorylation (OxPhos) levels and mitochondrial ATP production in both parental and Dabrafenib (HY-14660)-resistant SK-MEL-5 melanoma cells[2].
JWJ-01-306 (10 μM; 14 days) reduces the proliferative capacity of both parental and Dabrafenib-resistant SK-MEL-5 melanoma cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MIA PaCa-2 parental cells, MIA PaCa-2 sotorasib-resistant R2 cells
-
Concentration:10 μM (single-agent JWJ-01-306); 10 μM JWJ-01-306 plus 1 μM sotorasib (combination treatment)
-
Incubation Time:14 days
-
Result:Exerted only mild effects on proliferation over 14 days in parental MIA PaCa-2 cells.
Significantly impaired proliferation in combination with Sotorasib in Sotorasib-resistant MIA PaCa-2 R2 cells, while single-agent JWJ-01-306 had a moderate effect.
-
Cell Line:SUIT2 parental cells, SUIT2 MRTX1133-resistant cells
-
Concentration:10 μM (single-agent JWJ-01-306); 10 μM JWJ-01-306 plus 0.5 μM MRTX1133 (combination treatment)
-
Incubation Time:6 days
-
Result:Completely impaired proliferation within 5 days in parental SUIT2 cells.
Blocked cell growth as a single agent and in combination with MRTX1133 in MRTX1133-resistant SUIT2 cells.
-
Cell Line:sotorasib-resistant MIA PaCa-2 cells, sotorasib-resistant MIA PaCa-2 cells stably expressing ZBTB11WT or ZBTB11K866T
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Downregulated transcripts for 4 mitoribosome genes (MRPL48, MRPL44, MRPL1, MRPL30) and 4 complex I genes (NDUFS7, NDUFA12, NDUFC2, NDUFAF1).
Rescued JWJ-01-306-induced transcript downregulation for 7/8 downstream genes, and partially rescued MRPL1 transcript levels, when degradation-resistant ZBTB11K866T mutant was expressed.
-
Cell Line:parental and Dabrafenib-resistant (DABR) SK-MEL-5 melanoma cells
-
Concentration:10 μM
-
Incubation Time:14 days
-
Result:Reduced proliferation of both parental and Dabrafenib-resistant SK-MEL-5 cell lines as a single agent.
Parmacokinetics
| Species | Dose | Route | T1/2 | Cmax |
|---|---|---|---|---|
| Mice[1] | 10 mg/kg | i.p. | 91 min | 1.67 μM |
Chemical Information
-
CAS No. 3069975-17-0
-
분자량 574.98
-
화학식 C28H26ClF3N4O4
-
SMILES
FC(F)(F)C1=C(Cl)C=CC(CCNC2(CCC2)C3=CC(NC(C(N4C5CCC(NC5=O)=O)=O)=CC4=O)=CC=C3)=C1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
순도&문서
References
[1]. Tran NL, et al.. ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC. Nat Chem Biol. 2026 Feb;22(2):260-273. [Content Brief]
[2]. Jiang J, et al. Synthesis and Structure-Activity Relationships of CRBN-Recruiting ZBTB11 Molecular Glue Degraders. J Med Chem. 2025;68(18):19287-19302. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)